Influence of 6 genetic variants on the efficacy of statins in patients with dyslipidemia

Journal of Clinical Laboratory Analysis, EarlyView.
Source: Journal of Clinical Laboratory Analysis - Category: Laboratory Medicine Authors: Source Type: research

Related Links:

Conclusion: This study shows that SIM negatively affects the inflammatory and repair phases of the postinjury muscle regeneration. These findings are unique, strengthen the available knowledge on the side effects of SIM, and provide evidence showing that statin therapy is associated with an increased risk of impairment of the regenerative capacity of muscle. PMID: 30519583 [PubMed - in process]
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
HIGHER doses of statins could prevent 12,000 heart attacks and strokes a year, a study has found.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Authors: Gremese E, DE Lorenzis E, Ferraccioli GF PMID: 30504479 [PubMed - in process]
Source: Journal of Rheumatology - Category: Rheumatology Tags: J Rheumatol Source Type: research
CONCLUSION: These data suggest that better absorption and tissue distribution of BPF Phyto formulation represents an innovative approach in supplementation treatments of cardiometabolic disorders. PMID: 30501605 [PubMed - as supplied by publisher]
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
Measures of hospital quality, statin under- or over-use, Botox for AF, smoking cessation and translating trial evidence to clinical practice are discussed in this week ’ s podcast.theheart.org on Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
Publication date: Available online 6 December 2018Source: The Lancet Global HealthAuthor(s): Sanjay Basu, Ryan G Wagner, Ronel Sewpaul, Priscilla Reddy, Justine DaviesSummaryBackgroundCardiovascular diseases and their risk factors—particularly hypertension, dyslipidaemia, and diabetes—have become an increasing concern for middle-income countries. Using newly available, nationally representative data, we assessed how cardiovascular risk factors are distributed across subpopulations within South Africa and identified which cardiovascular treatments should be prioritised.MethodsWe created a demographically represe...
Source: The Lancet Global Health - Category: International Medicine & Public Health Source Type: research
Publication date: Available online 6 December 2018Source: Pharmacological ResearchAuthor(s): Krzysztof Dyrbus, Mariusz Gasior, Piotr Desperak, Jolanta Nowak, Tadeusz Osadnik, Maciej BanachAbstractDespite well-defined therapeutic low-density lipoprotein cholesterol (LDL-C) target in the highest-risk population, low percentage of patients is administered with intensive lipid-lowering therapy and achieves recommended levels. Therefore, based on the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry data we investigated the characteristics of lipid profile and management of dyslipidemia in acute coronar...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Publication date: December 2018Source: Canadian Journal of Cardiology, Volume 34, Issue 12Author(s): Liam R. Brunham, Isabelle Ruel, Sumayah Aljenedil, Jean-Baptiste Rivière, Alexis Baass, Jack V. Tu, G.B. John Mancini, Paolo Raggi, Milan Gupta, Patrick Couture, Glen J. Pearson, Jean Bergeron, Gordon A. Francis, Brian W. McCrindle, Katherine Morrison, Julie St-Pierre, Mélanie Henderson, Robert A. Hegele, Jacques Genest, Jeannette GoguenAbstractFamilial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals world...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Bempedoic acid (BA; ETC-1002) is a new agent that reduces cholesterol synthesis through inhibition of adenosine triphosphate citrate lyase, an enzyme upstream from 3-hydroxy-3-methylglutaryl-coenzyme A. In animal models, BA also influences fatty acid synthesis, but in humans, its role is limited primarily to lowering low-density lipoprotein cholesterol (LDL-C). In early clinical trials, BA was well tolerated and without major side effects. Alone or in various combinations with atorvastatin and/or ezetimibe, LDL-C lowering ranged from 17% to 64%. In addition, BA lowers levels of non–high-density lipoprotein cholestero...
Source: Cardiology in Review - Category: Cardiology Tags: New Therapy Update Source Type: research
A substantial proportion of older people who begin taking statins do not take them as intended, according to an Australian study published in the  British Journal of Clinical Pharmacology.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research
More News: Cholesterol | Genetics | Laboratory Medicine | Statin Therapy